Genmab A/S (NASDAQ:GMAB) Short Interest Update

Genmab A/S (NASDAQ:GMABGet Free Report) was the target of a large growth in short interest in March. As of March 15th, there was short interest totalling 2,050,000 shares, a growth of 10.2% from the February 29th total of 1,860,000 shares. Approximately 0.3% of the shares of the company are short sold. Based on an average daily trading volume, of 623,600 shares, the days-to-cover ratio is presently 3.3 days.

Genmab A/S Stock Down 1.0 %

GMAB opened at $29.96 on Wednesday. The stock has a fifty day moving average of $29.00 and a 200-day moving average of $30.84. The firm has a market capitalization of $19.80 billion, a P/E ratio of 31.21, a PEG ratio of 1.41 and a beta of 0.99. Genmab A/S has a 12-month low of $26.32 and a 12-month high of $42.99.

Genmab A/S (NASDAQ:GMABGet Free Report) last released its earnings results on Wednesday, February 14th. The company reported $0.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.02. The company had revenue of $675.29 million during the quarter, compared to analyst estimates of $678.14 million. Genmab A/S had a return on equity of 18.06% and a net margin of 26.50%. On average, analysts expect that Genmab A/S will post 1.09 earnings per share for the current fiscal year.

Institutional Trading of Genmab A/S

Several hedge funds and other institutional investors have recently modified their holdings of the company. Alliancebernstein L.P. raised its holdings in shares of Genmab A/S by 21.0% during the second quarter. Alliancebernstein L.P. now owns 8,187,576 shares of the company’s stock worth $311,210,000 after acquiring an additional 1,420,915 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Genmab A/S by 1.6% during the first quarter. BlackRock Inc. now owns 5,494,689 shares of the company’s stock worth $198,799,000 after acquiring an additional 86,571 shares in the last quarter. Capital International Investors raised its holdings in shares of Genmab A/S by 7.7% during the first quarter. Capital International Investors now owns 3,952,446 shares of the company’s stock worth $145,433,000 after acquiring an additional 283,031 shares in the last quarter. Macquarie Group Ltd. raised its holdings in shares of Genmab A/S by 11.1% during the first quarter. Macquarie Group Ltd. now owns 3,484,632 shares of the company’s stock worth $131,580,000 after acquiring an additional 347,437 shares in the last quarter. Finally, Wellington Management Group LLP raised its holdings in shares of Genmab A/S by 5.8% during the first quarter. Wellington Management Group LLP now owns 3,333,824 shares of the company’s stock worth $120,618,000 after acquiring an additional 183,578 shares in the last quarter. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on GMAB shares. BMO Capital Markets raised Genmab A/S from a “market perform” rating to an “outperform” rating and increased their price objective for the stock from $46.00 to $48.00 in a report on Friday, February 23rd. Morgan Stanley reaffirmed an “underweight” rating on shares of Genmab A/S in a research note on Tuesday, March 26th. Truist Financial reaffirmed a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a research note on Tuesday, March 26th. UBS Group raised Genmab A/S from a “neutral” rating to a “buy” rating in a research note on Wednesday, December 6th. Finally, Citigroup lowered Genmab A/S from a “neutral” rating to a “sell” rating in a research note on Monday, January 22nd. Three analysts have rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, Genmab A/S presently has an average rating of “Hold” and a consensus target price of $48.50.

Read Our Latest Stock Analysis on GMAB

About Genmab A/S

(Get Free Report)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Featured Stories

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.